Background: Numerous analogs of the antitumor agents epothilones A and B have been synthesized in search of better pharmacological pro¢les. Insights into the structure^activity relationships within the epothilone family are still needed and more potent and selective analogs of these compounds are in demand, both as biological tools and as chemotherapeutic agents, especially against drugresistant tumors.
Introduction
The clinical success of paclitaxel (PTX) and docetaxel in the treatment of cancer has prompted a worldwide search for compounds with a similar mechanism of action but improved characteristics. The low aqueous solubility of PTX and the development of clinical drug resistance, mediated by both the overexpression of P-glycoprotein (P-pg) and the presence of L-tubulin mutations [1] are factors that hamper its applicability. The discovery [2] and recognition of the epothilones as potent tubulin polymerizing agents [3] propelled them into the forefront of chemical and biological research (for review see [4] and references therein). Hailed as superior antitumor agents to PTX, epothilones A (1) and B (2) (Figure 1 ) stimulated several total syntheses [5^16] and construction of numerous analogs with promising pharmacological pro¢les [4] . These studies [4] hinted at the importance of the nitrogen of the side chain as well as of the macrocyclic scaffold and its substituents for the biological activity of these molecules. In this communication we report the design, chemical synthesis and biological evaluation of a series of pyridine epothilone B analogs which establish the crucial role of these structural features for potent tubulin binding and cytotoxicity. Remarkably, two of these new analogs proved to be more potent against a variety of human cancer cell lines than epothilone B, the most active of the naturally occurring epothilones.
Results and discussion

Molecular design and chemical synthesis of pyridine epothilones
The molecular design of the reported epothilone analogs (1^7, Figure 1 ) was based on (a) the fact that epothilone B (Epo B) is considerably more potent than epothilone A (Epo A); and (b) the assumption that the nitrogen atom of the side chain needed to be at the strategic position that is found in the natural epothilones. The pyridine ring linked appropriately at the 2-position (analog 1) was chosen as a substitute for the thiazole moiety. Molecular modeling [17] strongly suggested a role of this nitrogen as a hydrogen bond acceptor within the tubulin binding site, and to test this hypothesis the nitrogen atom was moved around the pyridine nucleus as in analogs 6 and 7. To increase the lipophilicity of the molecule, a methyl group was introduced in the pyridine ring at all possible positions (analogs 2^5). The designed pyridine epothilones 1^7 were synthesized via a convergent approach as outlined in Scheme 1. The strategy [18, 19] involved palladium-catalyzed coupling (Stille coupling) (for a recent review see [20] ) of a common precursor, vinyl iodide 11 [19] , with the appropriate pyridyl stannanes (13a^g, Scheme 2) providing directly the targeted compounds. Thus, the previously synthesized epothilone intermediate 8 [19] was selectively converted to tosylate 9 (TsCl, Et 3 N), and thence to iodide 10 (NaI, 75% overall yield for two steps). The latter compound (10) was reduced with NaBH 3 CN to afford the desired vinyl iodide 11 in 70% yield. The required pyridyl stannanes 13a^g were prepared from the corresponding, commercially available, bromopyridines 12a^g (Scheme 2) via metal^halogen exchange (nBuLi) followed by quenching with nBu 3 SnCl (40^89% yield, unoptimized). The Stille coupling of vinyl iodide 11 with stannanes 13a^g proceeded smoothly in the presence of PdCl 2 (MeCN) 2 , CuI and AsPh 3 to afford epothilone analogs 1^7 in 52^73% yield (unoptimized) as shown in Scheme 1. The newly synthesized analogs were chromatographically puri¢ed (silica gel) and fully characterized by spectroscopic means (see legend of Scheme 1).
Molecular modeling
The pyridine analogs of epothilones were docked into the pharmacophore-re¢ned tubulin model previously described [17] . Brie£y, constrained molecular mechanics minimizations using the class II force ¢eld (CVFF91) were performed on acceptable pyridine conformers. The conformers that were considered acceptable had no van der Waals overlap with tubulin atoms above 0.25 A î , after rotations were performed in 3³ increments, about the C15^C16 torsion. These rotatable bonds were explored until a full 360³ rotation was completed. The C16^C17 and C17^C18 bonds were planar to the pyridine rings due to conjugation and support through PM3 semiempirical calculations. Pyridine conformers with nitrogens that were not solvent-exposed were rejected. Acceptable conformers were extended to include the cis and trans isomers of the 16-methyl substituent relative to the solvent-accessible surface of tubulin. These docking studies were performed for both wild-type (1A9) and mutant tubulin models (PTX10, A8, and B10) where deemed appropriate based on biological activity.
Biological evaluation
The synthesized epothilones were screened for their ability to induce in vitro tubulin polymerization using the ¢l-tration colorimetric assay (see Materials and methods Section) and Epo B was retested for comparison purposes. This analysis was then followed by cytotoxicity studies in a set of ovarian carcinoma cell lines, including a parental cell line (1A9) and four drug-resistant cell lines, namely two paclitaxel-resistant cell lines (1A9/PTX10 and 1A9/ PTX22) [21] and two epothilone-resistant cell lines (1A9/ A8 and 1A9/B10) [17] (see Table 1 ). These resistant cell lines harbor distinct acquired L-tubulin mutations which affect drug^tubulin interaction and result in impaired taxane-and epothilone-driven tubulin polymerization. In the atomic model of KL-tubulin, these mutations are located near the taxane binding site [22] . The results of these biological investigations are summarized in Table 1 and reveal some important information for the structure^activ-ity relationship of these compounds.
In general, there is good agreement between the in vitro tubulin polymerization potency and the cytotoxicity pro¢le of all compounds tested. Interestingly, three compounds (1, 3 and 4) were more potent in the cell growth inhibition assay against the parental 1A9 cells than Epo B, the most active of the naturally occurring epothilones. All three compounds retained a cross-resistance pro¢le similar to Epo B against the four taxol-and Epo B-resistant cell lines revealing that substitution of the thiazole ring by a pyridine moiety (compound 1) or with a 4-or 5-methylpyridine system (compounds 3 and 4) is bene¢cial for biological activity (see below). Similarly to the thiazole side chain of Epo B, the presence of the nitrogen at the speci¢c location shown is crucial for the interaction with tubulin as it, presumably, serves as a hydrogen bond acceptor. The fact that a similar cytotoxicity pro¢le was obtained against the L-tubulin mutants potentially indicates that the conformation of these modi¢ed epothilones (1, 3 and 4) does not change upon binding to tubulin so that the same groups that are important for Epo B binding remain instrumental for the interaction of these compounds with tubulin. In addition, compound 4 was more active than Epo B or compound 3 against the Epo-resistant 1A9/A8 cell line (fold resistance factors: 25 for Epo B and compound 3, and 10 for compound 4) that harbors the L274 Thr3ILe mutation. This result suggests that the 5-methylpyridine system of compound 4 interacts more favorably with the hydrogenbonded solvent network mediated by Ile at position L274. Compound 2 was inactive both in vitro (0% tubulin polymerization) and in cells (IC 50 s 300 nM), i.e. placement of a methyl group at the 3-position of the pyridine ring results in total loss of activity. One possible explanation for this behavior is that the methyl group at the 3-position of the pyridine moiety forces the ring into an out-of-plane conformation with the neighboring double bond which is apparently unfavorable for binding to tubulin. Finally, compound 5 was much less potent than the parent Epo B, both in vitro and in cells, suggesting that the 6-methylpyridine substitution also leads to unfavorable changes in drug^tu-bulin interaction. The importance of the location of the nitrogen at the side chain was addressed by moving the nitrogen atom at two different positions on the pyridine ring. Molecular modeling predicted that the best position for the nitrogen atom would be the ortho position while relocation to the meta (compound 6) or para (compound 7) position would produce a signi¢cant loss of activity, with the rank order of activity being ortho s meta s para. This prediction was experimentally con¢rmed by both the in vitro tubulin polymerization and the cytotoxicity assay. As shown in Table 1 , compound 6 is 17-fold less active against the 1A9 parental cells as compared to compound 1 which has the nitrogen at the ortho position (IC 50 values, 1.7 and 0.1 nM, respectively) while compound 7 is 57.5-fold less active than compound 1 (IC 50 values, 5.75 and 0.1 nM, respectively). The biological properties of the synthesized epothilones were also evaluated in a panel of human cancer cell lines of distinct origin as summarized in Table 2 . In this table there are some cell lines resistant to PTX due to overexpression of P-gp. The cross-resistance pro¢le of pyridine epothilones against the P-gp overexpressing cell lines suggests that they are far less favorable substrates for P-gp than PTX. For example PTX is 5000-fold less active against MCF-7/ADR cells as compared to parental MCF-7 cells, while Epo B and compounds 1, 3, and 4 are only 10^22-fold less active. Moreover, Epo B and compounds 1^7 retain almost full activity against the KB-8511 cells, in contrast to PTX which is 238-fold less active in this cell line compared to the parental KB-31 cells. In addition, the results of Table 2 show that compounds 3 and 4 are consistently more potent that the parent Epo B against the panel of the 10 human cancer cell lines tested, while compound 1 appears to be less potent in most cell lines. Similarly to the results presented in Table 1 , compounds 6 and 7 are 14^39-fold less active than compound 1 against KB-31 cells, thus reinforcing the idea that the best placement for the nitrogen atom of the pyridine side chain is ortho to the attachment point of the ethenyl linker bridging the two ring domains of the epothilone structure.
The biological data for these pyridine epothilones are consistent with molecular docking experiments of these compounds within the common taxane-epothilone binding site according to our recently developed model of the interactions of Epo B with the energy-re¢ned tubulin structure [17] . Figure 2 depicts compound 4 bound to its receptor site and surrounded by residues L-V21, L-F270 and L-T274. Noteworthy is the lipophilic extension of this compound provided by the 5-methyl substituent and which reaches closer to the lipophilic pocket formed by the L-V21 residue leading to enhanced interaction (higher potency). This binding mode provides the basis for the structure activity relationship of analogs 1^7 by our docking studies.
For example, according to the model of compound 1, the unsubstituted pyridine is bulkier than the thiazole of Epo B. The model also indicates that this region of the taxane binding site is sterically restricted in such a way that the pyridine must occupy a conformation that is essentially Figure 2 . Stick model of compound 4 (carbon atoms in yellow) docked into an energy-re¢ned model of tubulin. The backbone ribbon structure of tubulin is green. Arrows point at two residues that confer taxane and epothilone resistance (L270 and L274) and at one residue (L21) that makes a favorable hydrophobic contact with the 5-methyl group of the pyridine ring of compound 4.
perpendicular to the solvent interface with tubulin. Such a conformation renders the pyridine nitrogen of 1 to be completely solvent-exposed which serves to facilitate hydrogen bonding with solvent. This modeling also indicates that the pyridine nitrogen that is ortho to the ring junction would be the only position on the pyridine where this hydrogen bond acceptor is completely solvent-exposed.
The docking of compound 6 where the nitrogen of the pyridine is meta relative to the ring junction indicates that the nitrogen would be only partially accessible to the solvent. This prediction was con¢rmed with the marked decrease in activity of compound 6. In addition, moving the pyridine nitrogen to the para position (as in compound 7) further reduced the activity of this compound. This was predicted by docking studies of compound 7 due to the complete inaccessibility of the pyridine nitrogen of 7 to solvent.
Our modeling studies also indicate that the preferred conformation of the pyridine with the ole¢n group attached to carbon 18 is planar. This is supported by the docked conformation of compound 2, where the methyl group at position 3 of the pyridine ring forces this ring out of plane with the ole¢n attached to 18. In this model, the entire side chain of 2 is parallel to the solvent-accessible surface of tubulin. This is a highly unfavorable binding mode, as the hydrophobic constituents of the pyridine ring are for the most part solvent-exposed. On the other hand, placing a methyl group at the 4-position of the pyridine ring (as in compound 3) enables the pyridine^C16^C17 ole¢n system to form a planar conformation and make favorable hydrophobic contacts with the side chain of Ala231. However, similar to 1, the extra bulk from the pyridine and methyl substituents imposes a steric restriction that shifts the entire molecule, including the macrolide ring system, approximately 1.0 A î away from the Epo B binding mode into the hydrogen-bonded network coordinated by Arg282 and Thr274. This may explain the increased sensitivity to both the epothilone-selected mutants A8 (L274) and B10 (L282) for compounds 1 and 3. This result is consistent with the docking study of compound 4. The placement of a methyl group onto pyridine, para to the ring junction (as in 4), has the opposite effect of the 4-methyl substituent in 3, or the absence of the methyl group in 1. The most important effect of this change is that the 5-methyl group of compound 4 increases the overall length of the epothilone pyridine structure. As a consequence, 4 repositions itself away from the Phe270 which results in the 7-OH group of the macrolide being 1.28 A î away from Epo B's hydrogen-bonded solvent network, which is coordinated by Arg282 and Thr274. This model also indicates that 4 still retains its solvent-mediated hydrogen bond with Thr274. This may explain why 4 is more active against the A8 and B10 mutant cells compared to 1 and 3.
Our modeling also explains the loss of activity of compound 5. Docking shows that its 6-methyl group of the pyridine is exposed to solvent which creates a signi¢cantly less favorable binding mode, and decreases at the same time the solvent accessibility of this pyridine nitrogen. In concert with the repositioning of the pyridine nitrogen (as in compounds 6 and 7), the previous ¢nding underscores the notion that a six-membered ring requires a strong hydrogen bond acceptor in this solvent-exposed portion, when bound to tubulin.
In summary, we have identi¢ed two compounds (3 and 4) with superior biological activity over the parent Epo B, the most potent of the naturally occurring epothilones. Compound 4, in particular, shows increased activity against the epothilone-resistant cell line A8 with a L274 tubulin mutation and is the most active of all the compounds tested against the P-gp overexpressing cell line MCF-7/ADR.
Signi¢cance
In conclusion, we have designed and synthesized a series of pyridine Epo B analogs, and established, through biological investigations and molecular modeling, the importance of the presence and location of the nitrogen for tubulin binding and cytotoxicity in these compounds. Most signi¢cantly, we have discovered that two of the newly synthesized pyridine epothilones exhibit more potent cytotoxic effects than Epo B against a wide variety of human cancer cells, including PTX-and Epo B-resistant cells. These ¢ndings are expected to aid further chemical biology studies and drug discovery efforts in the ¢eld of cancer chemotherapy.
Materials and methods
In vitro tubulin polymerization assay (Table 1) Tubulin polymerization was determined by the ¢ltration^colorimetric assay as previously described [3] . Brie£y, 1 mg/ml of puri¢ed tubulin was incubated at 37³C for 30 min with 5 WM of each compound in MEM buffer [100 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.75, 1 mM ethylene glycol bis(L-aminoethyl ether)-N,N,NP,NP-tetraacetic acid, 1 mM MgCl 2 ]. The mixture was then ¢ltered to remove unpolymerized tubulin in a 96-well ¢ltration plate (pore size, 0.22 Wm) and the collected polymerized tubulin was stained with amido black solution and quanti¢ed by measuring absorbance of the dyed solution on a microplate reader. The percent polymerization was calculated relative to the absorbance produced by incubation with 0.5 M GTP+10% glycerol in MEM (presumed to cause 100% polymerization).
In vitro tubulin polymerization assay (Table 2) Induction of tubulin polymerization was determined using a modi¢ed version of the microtubule protein centrifugation assay, as previously described [24] . MAP-associated porcine brain tubulin was incubated with 2 WM compound for 20 min. Percentage numbers indicate the relative degree of polymerization as compared to 25 WM Epo B, which under our experimental conditions caused s 95% of the total tubulin to polymerize.
Cell culture and cytotoxicity assay (Table 1) The epothilone-resistant cell lines 1A9/A8 and 1A9/B10 were isolated in a single step following exposure of the human ovarian carcinoma cell line A2780 (1A9) to lethal (IC 99 ) concentrations of either Epo A or B (IC 99 concentrations: 6 nM for Epo A and 0.5 nM for Epo B). After an initial expansion, the concentration of epothilones in the culture medium was gradually increased to 30 nM for Epo A and 5 nM for Epo B [17] . The isolation and characterization of the PTX-resistant cell lines 1A9/ PTX10 and 1A9/PTX22 has been described elsewhere [21] . Cells were maintained in a 5% CO 2 humidi¢ed atmosphere at 37³C in RPMI medium 1640 (Gibco BRL) containing 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 Wg/ml) (Gibco BRL). Prior to an experiment the 1A9/PTX10, 1A9/PTX22, 1A9/A8 and 1A9/B10 cells were cultured for at least 7^10 days in drug-free medium. Cytotoxicity assays were performed in 96-well plates using the sulforhodamine B assay as described previously [23] by seeding 500 cells/well and incubating with cytotoxic agents for 4 days.
Cytotoxicity assay (Table 2) Antiproliferative assays were performed as previously described [25] . Brie£y, cells were seeded at 1.5U10 3 /well into 96-well microtiter plates and incubated overnight. Compounds were added in serial dilutions on day 1. Subsequently, the plates were incubated for two population doublings (3^5 days) and then ¢xed with 3.3% v/v glutaraldehyde, washed with water and stained with 0.05% methylene blue. After washing, the dye was eluted with 3% v/v HCl and the optical density measured at 665 nm with a SpectraMax 340 (Bucherer, Basel, Switzerland). IC 50 values were determined by a computerized system (Softpro, Bucherer, Basel, Switzerland) using the formula (OD treated 3OD start )/ (OD control 3OD start )U100. IC 50 is de¢ned as the drug concentration which leads to 50% of cells per well as compared to control cultures (100%) at the end of the incubation period. The data represent the mean of three independent experiments.
